Japan - engelska - すりの適正使用協議会 RAD-AR Council, Japan

kissei pharmaceutical co., ltd. - darbepoetin alfa(genetical recombination)[darbepoetin alfa biosimilar1] - injection

Japan - engelska - すりの適正使用協議会 RAD-AR Council, Japan

kissei pharmaceutical co., ltd. - darbepoetin alfa(genetical recombination)[darbepoetin alfa biosimilar1] - injection

Europeiska unionen - litauiska - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetinas alfa - kidney failure, chronic; anemia; cancer - antianeminiai preparatai - simptominės anemijos, susijusios su lėtiniu inkstų nepakankamumu (crf), gydymas suaugusiems ir vaikams. gydymas simptominis anemija suaugusiųjų sergančių pacientų, su ne mieloidinių piktybinių navikų gauna chemoterapija.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

amgen europe b.v. - darbepoetinas alfa - anemia; cancer; kidney failure, chronic - kiti antianemic preparatai - simptominės anemijos, susijusios su lėtiniu inkstų nepakankamumu (crf), gydymas suaugusiems ir vaikams. gydymas simptominis anemija suaugusiųjų sergančių pacientų, su ne mieloidinių piktybinių navikų gauna chemoterapija.

Europeiska unionen - tjeckiska - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetin alfa - kidney failure, chronic; anemia; cancer - antianemické přípravky - léčba symptomatické anémie spojené s chronickým selháním ledvin (crf) u dospělých a pediatrických pacientů. léčba symptomatické anémie u dospělých pacientů s nemyeloidními malignitami, kteří jsou chemoterapie.

Europeiska unionen - slovakiska - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetínu alfa - kidney failure, chronic; anemia; cancer - antianemické prípravky - liečba symptomatickej anémie spojenej s chronickým zlyhaním obličiek (crf) u dospelých a detských pacientov. liečbu symptomatických anémia u dospelých pacientov s rakovinou s non-myeloidná malignancies dostávajú chemoterapiu.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: water for injections; polysorbate 80; dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - engelska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - engelska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy